Fleree is commonly used in clinical settings involving the acute risk of conception following unprotected sexual intercourse or a suspected failure in a routine contraceptive method. This medication is applied as a progestin-only emergency contraceptive, relevant in contexts where short-term symptomatic assistance is needed for pregnancy prevention.

The medicine's utility is considered relevant within a critical postcoital time window, where its application is helpful in situations requiring additional management of discomfort. It is relevant in clinical situations marked by a sudden lapse in contraceptive protection (such as a missed dose or mechanical failure) and is also applied in settings involving the acute risk arising from an unplanned sexual encounter. The core benefit is that it supports patients during difficult episodes by easing distress related to the risk following exposure.

“The therapeutic benefit supports a time-sensitive application that helps patients cope more steadily with the urgent context.”

This medication is relevant for managing the symptomatic burden linked to the risk following unprotected intercourse or a known or suspected contraceptive failure.

Quick Fact: Relief for Acute Contraceptive Compromise

Eligibility Map: Who Can and Cannot Use Fleree — Official Regulatory Information

Eligibility classifications (high-level)

The severity classification relies on terms like Contraindicated (for pregnancy and hypersensitivity) and Not Recommended (for severe hepatic dysfunction). The regulatory basis for these rules is defined by official FDA Prescribing Information and EMA Summaries of Product Characteristics for levonorgestrel.

Resulting eligibility structure

Official eligibility statements:

• Fleree is contraindicated in women with a known or suspected pregnancy or those with hypersensitivity to the ingredients.
• The medicine is approved only for females of childbearing potential and is not intended for use in pre-menarcheal or postmenopausal women.
• Use is not recommended in the presence of severe hepatic dysfunction and is not indicated for routine use.

Connection to the overall eligibility profile: Regulatory documents define eligibility by establishing pregnancy and ingredient hypersensitivity as absolute contraindications for use. Eligibility is otherwise restricted to the reproductive age range, with restrictions focusing on conditions that may compromise the body's ability to absorb or process the drug, such as severe liver impairment.

Interactions with other medicines and products

Fleree's interaction profile, defined by regulatory authorities, centers primarily on pharmacokinetic interactions that alter the concentration of its active ingredient, levonorgestrel.

The core constraint defined in official documents involves medicines and herbal products that are liver enzyme inducers, mainly affecting the CYP3A4 metabolic pathway. This enhanced metabolism may lead to a clinically significant reduction in levonorgestrel exposure, which is why regulatory bodies have issued guidance regarding the use of non-hormonal emergency contraception or alternative dosing in women who have recently used such inducers (within the preceding four weeks).

Separately, the use of Fleree is not recommended in patient populations with severe hepatic dysfunction due to potential impairment of drug metabolism.

Fleree is a levonorgestrel-releasing intrauterine system that functions predominantly through a localized pharmacodynamic mechanism within the endometrium and cervix. The released levonorgestrel is a synthetic progestin that acts as an agonist at the progesterone receptor (PR). Within the uterus, the direct local presence of levonorgestrel causes extensive decidualization of endometrial stromal cells and atrophy of the glandular and surface epithelium. This cellular modification results in endometrial thinning and renders the local environment non-receptive. Simultaneously, the compound induces a downregulation of local endometrial estrogen receptors, which diminishes the tissue's responsiveness to circulating estradiol. In the cervix, levonorgestrel exposure causes an increase in the viscosity and cellularity of the cervical mucus. This thickening physically impedes the passage and motility of sperm through the cervical canal. The combined intracellular and tissue-level effects modulate several system-level physiological processes: they inhibit sperm mobility and function within the female reproductive tract and create a non-receptive uterine lining, thereby modifying reproductive cellular processes.

How to Use Fleree — Administration Guidelines

Fleree (levonorgestrel) is administered as a single, time-critical intervention and is not intended for routine use as a contraceptive method. Guidelines define its use based on adherence to a specific route, dose, and time window.

Administration Scope

Procedural Context

Following the administration of the dose, it is recommended to use a barrier method (e.g., condom) for subsequent intercourse until the next menstrual period begins. The total dose for a single course of treatment is 1.5 mg of levonorgestrel.

Special consideration for dose adjustment is noted for individuals taking certain enzyme-inducing drugs (e.g., rifampicin); in such cases, a double dose (total 3 mg) may be recommended if a non-hormonal method is unavailable.

Research Evidence / Overview of Studies for Fleree

Evidence for Use following Unprotected Intercourse

The core research for Fleree (levonorgestrel) has primarily focused on its clinical evaluation for use following unprotected intercourse, where the outcome examined is unintended pregnancy. The evidence base includes robust designs such as short-term Randomized Controlled Trials (RCTs), where different approaches were compared, as well as comprehensive systematic reviews and meta-analyses that combine data from multiple individual studies. Fleree was evaluated in research contexts focusing on the time-sensitive nature of postcoital contraception.

Studies monitored healthy women of reproductive age who presented in this specific research scenario. The findings describe patterns observed in the studies, where pregnancy incidence was the primary measured endpoint. Research also describes how symptoms evolved in the observed populations related to changes in the timing of the subsequent menstrual period.

Evaluating Outcomes in Clinical Studies

The clinical trials were designed to measure two primary categories of outcomes. The first and most critical was an outcome reflecting daily functioning or activity level: the recorded incidence of pregnancy in the study groups. The second category involved outcomes related to physiological strain or stress, specifically monitoring and reporting on the changes or disruptions to the timing of the next expected menstrual cycle.

Research in Specific Populations and Subgroups

Fleree was studied for its use across the broad population of women of reproductive age, including adolescents. Research examined the outcomes for postpubertal adolescents, and studies included comparisons of findings for this age range against those for older users. However, the evidence derived from specific research scenarios is sometimes more complex when considering women with varying Body Mass Index (BMI) levels.

Research has explored outcomes in groups categorized by higher body weight or BMI. Studies report that the findings were mixed regarding the primary measured outcome in these groups. Subsequent regulatory reviews have described the evidence quality as varying across studies, noting that subgroup evidence derived from some populations remains uncertain regarding the influence of body weight on the observed outcome.

Common questions about Fleree (FAQ)

Q: What is the main difference between Fleree and other drugs used for the same condition?

A: Fleree's active ingredient, levonorgestrel, is one common type of emergency contraception, often referred to as a progestin-only method. Official documents indicate that its primary action is to prevent or delay ovulation (the release of an egg) and modify the uterine lining. Regulatory sources note that other emergency contraception methods, such as those containing Ulipristal acetate, are available and function under different regulatory parameters, including different time windows for administration.

Q: How long does it usually take to notice the effects of Fleree?

A: Official regulatory documents indicate that the active ingredient, levonorgestrel, is rapidly absorbed after you take the tablet. The blood concentration typically peaks within approximately 1 to 3 hours. The rise in concentration means the active ingredient is available to begin its physiological function, such as modifying the cervical mucus and endometrium.

Q: Is it okay to stop taking Fleree suddenly?

A: Fleree (Levonorgestrel) is designed as a single-dose, one-time intervention and is not intended for routine or continued use. Therefore, once the required single dose has been taken within the official time frame, the administration is complete and no further action is required.

Q: What are the most common reasons people are prescribed Fleree?

A: Fleree is officially indicated for the prevention of pregnancy following an act of unprotected intercourse or when a regular contraceptive method is known or suspected to have failed. Regulatory documents consistently describe it as a backup method for emergencies, not as a primary form of birth control.

Q: Is it true that Fleree can cause weight changes?

A: Official regulatory documents and safety classifications for Fleree (Levonorgestrel) emergency contraception do not list weight changes (gain or loss) as a common or very common adverse reaction. The most frequent side effects are typically temporary and related to hormonal effects, such as headache and nausea.

Q: Can Fleree be taken by people over the age of 65?

A: Fleree is specifically indicated and studied for use in women of reproductive age, which includes postpubertal adolescents and women in their childbearing years. Official product information does not provide recommendations or data for its use in women over the age of 65, as the indication is for emergency contraception.

Q: Is Fleree safe for people with a history of heart issues?

A: Official regulatory warnings list a very rare risk of serious thromboembolic events (blood clots). Contraindications may include active thromboembolic disease. Specific regulatory warnings exist for patients with severe renal or cardiovascular dysfunction, where the potential for fluid retention is a concern described in official documents.

Q: What happens if Fleree is taken in combination with alcohol?

A: Official labeling does not list alcohol as an interacting substance that directly reduces the effectiveness of Fleree. However, consuming alcohol may increase the severity of common side effects, such as dizziness, nausea, and headache. If vomiting occurs within the specified time window after administration, official guidelines advise repeating the dose, independent of the cause.

Q: Does the effectiveness of Fleree decrease over time?

A: Studies and official product information show that Fleree's effectiveness decreases the longer the time period is between unprotected intercourse and taking the medication. Furthermore, Fleree is not intended for routine or repeated use within the same menstrual cycle, and repeated use may lead to irregular bleeding without confirmed efficacy.

Q: Is Fleree suitable for use during pregnancy or while breastfeeding?

A: Fleree is contraindicated (should not be used) in cases of known or suspected existing pregnancy, as it is not effective in terminating an established pregnancy. Regulatory documents also note that small amounts of levonorgestrel do pass into breast milk. Use of the medication while breastfeeding is a topic for discussion with a healthcare professional.

Q: Does Fleree have a risk of dependence or addiction?

A: Official labeling states that the active ingredient, levonorgestrel, is not classified as a controlled substance. According to official regulatory documents, there is no known information about dependence or addiction associated with the use of Fleree emergency contraception.

Q: Can Fleree be crushed or split if it's hard to swallow?

A: The regulatory instructions for taking the tablet dosage form require that the tablet be swallowed whole with water. Official labeling documents do not contain instructions for manipulating the tablet in any way, such as crushing or splitting it.

Q: Is Fleree only for chronic conditions or can it be used short-term?

A: Official labeling is clear that Fleree is strictly a single, short-term, time-critical intervention for emergency contraception. It is not intended for routine use and is not a treatment for any long-term or chronic condition.

Q: What are the typical age ranges for people who use Fleree?

A: Fleree is indicated for use in women of reproductive age, a group that includes postpubertal adolescents. This definition covers women throughout their full childbearing years.

Q: What should I do if I miss taking Fleree?

A: The official instruction is to take Fleree as soon as possible and absolutely within 72 hours (3 days) of unprotected intercourse. If the 72-hour window has passed, the efficacy of the medicine may be reduced. In this event, information on alternative emergency contraception methods should be sought.

Q: Are there any foods or drinks that should be avoided while taking Fleree?

A: Official labeling primarily focuses on drug and herbal interactions. However, compounds found in grapefruit juice can inhibit a liver enzyme involved in breaking down levonorgestrel. This may potentially increase the concentration of Fleree in the body. Regulatory documents indicate that patients may be instructed to limit their intake of grapefruit juice.

Q: Is Fleree safe to use if I have an existing kidney problem?

A: Official regulatory documents specifically cite severe hepatic impairment (liver dysfunction) as a constraint for use. While kidney disease is not listed as a direct contraindication, caution is noted for patients with severe renal dysfunction due to the potential for fluid retention.

Q: Is Fleree a type of steroid?

A: Fleree's active ingredient, levonorgestrel, is chemically classified as a progestin, which is a synthetic compound similar to the body’s natural hormone, progesterone. Progestins are part of the broader steroid hormone class but are not the same as corticosteroids (like prednisone).

Q: Is there a generic version of Fleree available?

A: Fleree is a brand name for the active ingredient, levonorgestrel. According to regulatory listings, 1.5 mg tablets containing levonorgestrel are widely available and marketed under numerous brand names, as well as being sold as generic medicines.

Q: Does Fleree require regular blood tests?

A: Fleree is a single-dose intervention for emergency contraception. Regulatory guidance confirms that the medication does not require regular follow-up blood tests related to the drug's administration or long-term safety monitoring.

Q: How long does Fleree stay in the body after I stop taking it?

A: Official pharmacokinetics data states that levonorgestrel has an elimination half-life of approximately 20 to 32 hours. Based on this, it typically takes several days (about 5 to 7 days) for the active ingredient to be almost completely eliminated from the body.

Q: Can Fleree make existing mental health conditions worse?

A: While mental health changes are not typically listed as common side effects for the emergency dose, studies related to higher-dose, routine hormonal use have examined potential associations with psychiatric symptoms, such as depression. Patients with a history of mental health conditions may wish to discuss this with a healthcare professional.

Q: Why are there warnings about Fleree and grapefruit juice?

A: The concern is related to pharmacokinetic interactions. Grapefruit juice can inhibit a specific enzyme (CYP3A4) in the gut that helps metabolize, or break down, levonorgestrel. Inhibiting this enzyme could potentially increase the amount of levonorgestrel in the body.

Q: What is the proper way to store Fleree?

A: Official regulatory guidance requires that Fleree tablets be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The product must be kept in the original blister packaging to protect it from light and moisture.

Q: What are the steps for properly disposing of Fleree?

A: Regulatory guidance suggests disposing of unused or expired Fleree tablets through a formal drug take-back program when one is available. If no such program exists, the tablets can be mixed with an unappealing substance, sealed in a container, and then placed in the household trash. Regulatory guidance notes that tablets are not typically listed for disposal by flushing down the toilet.

Q: Can Fleree affect laboratory test results?

A: As a hormonal compound, levonorgestrel may potentially influence the results of certain endocrine function and coagulation laboratory tests. This is relevant information that may need to be provided to laboratory technicians and healthcare providers prior to testing.

Q: Does Fleree change how other medications are absorbed?

A: Official regulatory documents specify that levonorgestrel may inhibit the metabolism of certain co-administered drugs, such as Cyclosporine, which could lead to increased exposure to that drug. There is no general regulatory warning stating that Fleree alters the absorption rate of all other medications.

Q: Are there any known interactions between Fleree and vaccines?

A: Regulatory documents focus on specific drug-drug and drug-herbal interactions that affect the metabolism of levonorgestrel. There are no known officially documented interactions between Fleree (Levonorgestrel) and vaccinations listed in regulatory documents.

Q: Is there a specific population for whom Fleree is not recommended?

A: Fleree is officially not recommended for use in patients with severe hepatic impairment (liver dysfunction) and is contraindicated in cases of known or suspected pregnancy. The medication is also not recommended for use as routine contraception.

Q: How does Fleree fit into a complete treatment plan?

A: Fleree’s role is strictly as a single, one-time intervention for emergency contraception. It is not intended to be part of a long-term treatment plan. Following its use, official guidance states that a user must initiate or resume a reliable form of routine contraception, as Fleree does not provide any ongoing protection.

How to Store and Dispose of Fleree

Official regulatory guidelines mandate specific storage and disposal requirements for Fleree (levonorgestrel) tablets to ensure the product's quality and safety.

Storage Requirements

The tablets must be maintained at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions. It is essential to keep the product from freezing and protect it from both light and moisture. Fleree must be stored in its original package to preserve its integrity and must always be kept out of the reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for medicinal products. Medication should not be discarded in wastewater or household waste unless specifically authorized by local environmental regulations.